Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of the American Society of Nephrology : JASN|March 28, 2006
Lipids and renal diseaseRoberto Trevisan, Alessandro R Dodesini, Giuseppe Lepore
Rivista Di Psichiatria|January 14, 2010
[Implementation of a psycho-educational program for guests of a residential facilities in the area of Bari to develop a better adherence to drug treatment]Giuseppe Lepore, Anna Maria Piperis, Maria Pia Sacco
Diabetes Technology & Therapeutics|October 17, 2019
Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control StudyGiuseppe Lepore, Cristiana Scaranna, Anna Corsi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 25, 2020
ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with DulaglutideAntonio C Bossi, Valentina De Mori, Cristiana Scaranna, et al.
Acta Diabetologica|July 20, 2022
Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose controlGiuseppe Lepore, Alessandro Rossini, Rosalia Bellante, et al.
The Journal of Clinical Endocrinology and Metabolism|November 22, 2023
Development of a New Model of Insulin Sensitivity in Patients With Type 2 Diabetes and Association With MortalityStefano Ciardullo, Alessandro Roberto Dodesini, Giuseppe Lepore, et al.
Diabetes Technology & Therapeutics|September 15, 2021
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 UsersJulien Da Silva, Giuseppe Lepore, Tadej Battelino, et al.
Acta Diabetologica|November 22, 2024
Comparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systemsNicolò Diego Borella, Antonio Ferramosca, Giona Castagna, et al.
Journal of Diabetes Science and Technology|January 7, 2025
Different Times for Different Metrics: Predicting 90 Days of Intermittently Scanned Continuous Glucose Monitoring Data in Subjects With Type 1 Diabetes on Multiple Daily Injection Therapy. Findings From a Multicentric Real-World StudyAlessandro Csermely, Nicolò D Borella, Anna Turazzini, et al.
Diabetes Technology & Therapeutics|October 30, 2023
Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best EfficacyGiuseppe Lepore, Nicolò Diego Borella, Giona Castagna, et al.
Pageof 2